Profile of anticonvulsant activity and neuroprotective effects of novel and potential antiepileptic drugs - An update

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 719-733

  Stepień, Karolina ^a   Tomaszewski, Michał ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Animal model of seizures; Antiepileptic drug; Antiepileptic drugs; Mode of action; Neurodegeneration; Neuroprotection

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DANTROLENE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; IBUPROFEN; LAMOTRIGINE; LOSIGAMONE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; REMACEMIDE; TALAMPANEL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; HUMAN; INDUCED HYPOTHERMIA; LIVER TOXICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PSYCHOSIS; REVIEW; SOMNOLENCE; THERAPY RESISTANCE; VISUAL FIELD DEFECT; VOMITING;

EID: 33645690471     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Ambrosio AF, Silva AP, Araujo I, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM: Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA-2-024. Eur J Pharmacol, 2000, 406, 191-201.
2. Andre V, Rigoulot MA, Koning E, Ferrandon A, Nehlig A: Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia, 2003, 44, 893-903.
3. Baulac M, Klement S: Efficacy and safety of losigamone in partial seizures: a randomized double-blind study. Epilepsy Res, 2003, 55, 177-189.
4. Belayev L, Alonso OF, Liu Y, Chappell AS, Zhao W, Ginsberg MD, Busto R: Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J Neurotrauma, 2001, 18, 1031-1038.
5. Besag FM: Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf, 2004, 3, 1-8.
6. Beydoun A, Schmidt D, D-Souza J: Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. J Pain, 2002, 3, Suppl 1, 38-42.
7. Bialer M, Johannessen JC, Kupferberg HJ, Levy RH, Loiseau P, Perucca E: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res, 2002, 51, 31-71.
8. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca Em Tomson T: Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res, 2004, 61, 1-48.
9. Bootsma HPR, Coolen F, Aldenkamp AP, Arends J, Diepman L, Hulsman J, Lambrechts D et al.: Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to tertiary epilepsy center. Epilepsy Behav, 2004, 5, 380-387.
10. Borowicz KK, Ratnaraj N, Patsalos PN, Czuczwar SJ: Effect of felbamate and its combinations with conventional antiepileptics in amygdala-kindled rats. Pharmacol Biochem Behav, 2004, 78,103-110.
11. Borowicz KK, Stasiuk G, Teter J, Kleinrok Z, Gasior M, Czuczwar SJ: Low propensity of conventional antiepileptic drugs for interactions with felbamate against maximal electroshock-induced seizures in mice. J Neural Transm, 2000, 177, 733-743.
12. Borowicz KK, Świader M, Łuszczki J, Czuczwar SJ: Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia, 2002, 43, 956-963.
13. Borowicz KK, Świader M, Zgrajka W, Sawulski C, Turski WA, Czuczwar SJ: Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. J Physiol Pharmacol, 2002, 53, 859-869.
14. Bouwman BM, van den Broekb VPC, van Luijtelaar G, van Rijn CM: The effects of vigabatrin on type II spike wave discharges in rats. Neurosci Lett, 2003, 338, 177-180.
15. Calabresi P, Marti M, Picconi B, Saulle E, Costa C, Centonze D, Pisani F et al.: Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. Exp Neurol, 2003,182, 461-469.
16. Chadwick DW, Betts TA, Boddie HG, Crawford PM, Lindstrom P, Newman PK, Soryal I et al.: Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure, 2002, 11, 114-123.
17. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J et al.: A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology, 2002, 58, 1680-1682.
18. Czapiński P, Blaszczyk B, Czuczwar SJ: Mechanisms of action of antiepileptic drugs. Curr Top Med Chem, 2005, 5, 3-14.
19. Czuczwar K, Czuczwar M, Cieszczyk J, Gawlik P, Łuszczki J, Borowicz KK, Czuczwar SJ: Neuroprotective activity of antiepileptic drugs. Przeg Lek, 2004, 61, 1268-1271 [in Polish].
20. Czuczwar SJ, Borowicz KK: Polytherapy in epilepsy: the experimental evidence. Epilepsy Res, 2002, 52, 15-23.
21. Czuczwar SJ, Patsalos PN: The new generation of GABA enhancers potential in the treatment of epilepsy. CNS Drugs, 2001, 15, 339-350.
22. Czuczwar SJ, Świader M, Kuźniar H, Gasior M, Kleinrok Z: LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol, 1998, 359, 103-109.
23. Danysz W, Parsons CG: Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res, 2002, 4, 119-126.
24. Devinsky O, Vazquez B, Faught E, Leppik IE, Pellock JM, Schachter S, Alderfer et al.: A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment. Seizure, 2002, 11, 371-376.
25. Errante L D, Petroff OC: Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure, 2003, 12, 300-306.
26. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn SJ, Cohn CK, Shrivastava RK, Targum SD et al.: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol, 2003, 23, 240-249.
27. Fisher A, Wang X, Cock HR, Thom M, Patsalos PN, Walker MC: Synergism between topiramate and budipine in refractory status epilepticus in the rat. Epilepsia, 2004, 45, 1300-1307.
28. Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, Volpe JJ et al.: Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J Neurosci, 2004, 24, 4412-4420.
29. Frahm C, Stief F, Zuschratter W, Draguhn A: Unaltered control of extracellular GABA-concentration through GAT-1 in the hippocampus of rats after pilocarpine-induced status epilepticus. Epilepsy Res, 2003, 52, 243-252.
30. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2004, 62, 1252-1260.
31. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2004, 62, 1261-1273.
32. Friis M L, Kristensen O, Boas J, Dalby M, Beth SH, Gram L, Mikkelsen M et al.: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand, 1993, 87, 224-227.
33. Garske GE, Palmer GC, Napier JJ, Griffith RC, Friedman LR, Harris EW, Ray R et al.: Preclinical profile of anticonvulsant remacemide and its enantiomers in rat. Epilepsy Res, 1991, 9, 161-174.
34. Gates JR: Using new antiepileptic drugs as monotherapy. Curr Treat Options Neurol, 2004, 6, 223-230.
35. Halasz P, Rasonyi G: Neuroprotection and epilepsy. Adv Exp Med Biol, 2004, 541, 191-109.
36. Harnon E, Klitgaard H: Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure, 2001, 10, 287-293.
37. Hashimoto Y, Suemaru K, Yamamoto T, Kawakami K, Araki H, Yutaka G: Effect of immobilization stress on anticonvulsant actions and pharmacokinetics of zonisamide in mice. Pharmacol Biochem Behav, 2001, 68, 7-12.
38. Hill CM, Balkenohl M, Thomas DW, Walker R, Mathé R, Murray G: Pregabalin in patients with postoperative dental pain. Eur J Pain, 2001, 5, 119-124.
39. Hilton EJR, Hosking SL, Betts T: The effect of antiepileptic drugs on visual performance. Seizure, 2004, 13, 113-128.
40. Ikonomidou C: Antiepileptic drugs as pro-apoptotic agents in the developing brain: mechanism for adverse neurobehavioral outcomes? Epilepsia 2004, 45, Suppl 3, 209-210.
41. Janz R, Goda Y, Geppert M, Missler M, Sudhof T: SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron, 2003, 24, 1003-1016.
42. Jones MW, Blume WT, Guberman A, Lee MA, Pillay N, Weaver DF, Veloso F et al.: Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen. Seizure, 2002, 11, 104-113.
43. - cotransporter. Mol Brain Res, 2003,114, 86-90.
44. Karkar KM, Thio LL, Yamada KA: Effects of seven clinically important antiepileptic drugs on inhibitory glycine receptor currents in hippocampal neurons. Epilepsy Res, 2004, 58, 27-35.
45. Kawada K, Itoh S, Kusaka T, Isobe K, Ishii M: Pharmacokinetics of zonisamide in perinatal period. Brain Dev, 2002, 24, 95-97.
46. Kimber-Trojnar Z, Borowicz KK, Malek R, Sobieszek G, Piskorska B, Czuczwar SJ: Perspectives of losigamone in epilepsy treatment. Pol J Pharmacol, 2003, 55, 675-682.
47. Klitgaard H, Pitkanen A: Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord, 2003, 5, S9-16.
48. Lagae L, Buyse G, Deconinck A, Ceulemans B: Effect of levetiracetam in refractory chilhood epilepsy syndromes. Eur J Pediatr Neurol, 2003, 7, 123-128.
49. Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, Patsalos PN: Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia, 2003, 44, 46-53.
50. Leach JP, Marson AG, Hutton JL: Remacemide for drug-resistant localization-related epilepsy. Cochrane Database Syst Rev, 2002, 4, CD001900.
51. Leker RR, Neufeld MY: Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain Res, 2003, 42, 187-203.
52. Leppik IE: Zonisamide. Epilepsia, 1999, 40, Suppl 5, S23-S29.
53. Lhatoo SD, Wong ICK, Polizzi G, Sander JWAS: Longterm retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia, 2000, 41, 1592-1596.
54. Liu Y, Barks JD, Xu G, Silverstein FS: Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke, 2004, 35, 1460-1465.
55. Lodge D, Bond A, O'Neill M J, Hicks C A, Jones M G: Stereoselective effects of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies. Neuropharmacology, 1996, 35, 1681-1688.
56. Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Bajjellieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA, 2004, 101, 9861-9866.
57. Łuszczki JJ, Czuczwar SJ: Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res, 2003,56, 27-42.
58. Łuszczki JJ, Czuczwar SJ: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369, 434-446.
59. Łuszczki J, Wójcik-Ćwikła J, Andres MM, Czuczwar SJ: Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 2004, 30, 958-973.
60. Małek R, Borowicz KK, Kimber-Trojnar Z, Sobieszek G, Piskorska B, Czuczwar SJ: Remacemide - a novel potential antiepileptic drug. Pol J Pharmacol, 2003, 55, 691-698.
61. Maragakis NJ, Jackson M, Ganel R, Rothstein JD: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett, 2003, 338, 107-110.
62. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG: Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res, 2004, 58, 167-174.
63. Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo E, Lalonde R: Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther, 2003, 73, 491-505.
64. Mitchell WG, Shah NS: Vigabatrin for infantile spasms. Pediatr Neurol, 2002, 27, 161-164.
65. Newmark ME, Dubinsky S: Zonisamide monotherapy in a multi-group clinic. Seizure, 2004, 13, 223-225.
66. Noldner M, Chatterjee SS: Losigamone. Drugs Future, 1990, 15, 995-996.
67. Norris SK, King AE: Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro. Neuropharmacology, 1997, 36, 951-959.
68. Oommen KJ, Mathews S: Zonisamide: a new antiepileptic drug. Clin Neuropharmacol, 2002, 192-200.
69. Palmer GC, Murray RJ, Wilson TC: Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide. Epilepsy Res, 1992, 12, 9-20.
70. Pappalardo A, Liberto A, Patti F, Reggio A: Neuroprotective effects of topiramate, Clin Ter, 2004, 155, 75-78.
71. Patsalos PN: Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43, 707-724.
72. Pisani F, Pedale S, Macaione V, Torre V, Oteri G, Avanzini G, lentile R: Neuroprotective effects of lamotrigine and remacemide on excitotoxity induced by glutamate agonists in isolated chick retina. Exp Neurol, 2001, 170, 162-170.
73. Pitkanen A: Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res, 2002, 50, 141-160.
74. Pitkanen A: New pharmacotherapy for epilepsy. Drugs, 2004, 7, 471-477.
75. Reijs R, Aldenkamp AP, De Krom M: Mood effects of antiepileptic drugs. Epilepsy Behav, 2004, 5, S66-S76.
76. Rekling JC: Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett, 2003, 335, 167-170.
77. Rigoulot MA, Koning E, Ferrandon A, Nehlig A: Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther, 2004, 308, 787-795.
78. Schmidt D, Elger CE: What is the evidence that oxcarbazepine and carbamazepine are directly different antiepileptic drugs? Epilepsy Behav, 2004, 5, 627-635.
79. Schwabe K, Ebert E, Loscher BW: Bilateral microinjections of vigabatrin in the central piriform cortex retard amygdala kindling in rats. Neuroscience, 2004, 129, 425-429.
80. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Małek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol, 2002, 55, 683-689.
81. Shorvon S: Oxcarbazepine: a review. Seizure, 2000, 9, 75-79.
82. Sills GJ, Butler E, Thompson GG, Brodie MJ: Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure, 2004, 13, 287-295.
83. Stein U: Potential antiepileptic drugs: losigamone. In: Antiepileptic Drugs. Ed. Levy RH, Mattson RH, Meldrum BS, Raven Press, New York, 1995, 1025-1034.
84. Świader M, Borowicz KK, Porebiak J, Kleinrok Z, Czuczwar SJ: Influence of agents affecting voltage-dependent calcium channels and dantrolene on the anticonvulsant action of the AMPA/kainate receptor antagonist LY 300164 in mice. Eur Neuropsychopharmacol, 2002, 12, 311-319.
85. Świader M, Kotowski J, Gasior M, Kleinrok Z, Czuczwar SJ: Interaction of topiramate with conventional antiepileptic drugs in mice. Eur J Pharmacol, 2000, 399, 35-41.
86. Świader M, Kuźniar H, Kleinrok Z, Czuczwar SJ: Influence of LY 300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice. Pol J Pharmacol, 2003, 55, 103-107.
87. Świader M, Łuszczki J, Wielosz M, Czuczwar SJ: Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. Pol J Pharmacol, 2003, 55, 363-370.
88. Trojnar MK, Małek R, Chrościńska M, Nowak S, Błaszczyk B, Czuczwar SJ: Neuroprotective effects of antiepileptic drugs. Pol J Pharmacol, 2002, 54, 557-566.
89. Turnheim K: Drug interactions with antiepileptic agents. Wien Klin Wochenschr, 2004, 116, 112-118.
90. Van Parys JA, Meinardi H: Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named patient basis. Epilepsy Res, 1994, 19, 79-85.
91. Vilagi I, Takacs J, Gulyas-Kovacs A, Banczerowski-Pelyhe I, Tarnawa I: Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res Bull, 2002, 59, 35-40.
92. Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ: Levetiracetam: preliminary experience in patients with primary brain tumors. Seizure, 2003, 12, 585-586.